<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IMPAVIDO- miltefosineÂ capsuleÂ </strong><br>Paladin Therapeutics Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use IMPAVIDO safely and effectively.  See full prescribing information for IMPAVIDO.<br><br>IMPAVIDO (miltefosine) capsules, for oral use<br>Initial U.S. Approval: 2014</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: EMBRYO-FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">IMPAVIDO may cause fetal harm. <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, occurred in animals administered miltefosine at doses lower than the recommended human dose.  Do not administer IMPAVIDO to pregnant women. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing IMPAVIDO.  </span> </p>
<p class="Highlighta"><span class="Bold">Advise females of reproductive potential to use effective contraception during therapy and for 5 months after therapy (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>, <a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>, <a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>, <a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>).</span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: EMBRYO-FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">IMPAVIDO may cause fetal harm. <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, occurred in animals administered miltefosine at doses lower than the recommended human dose.  Do not administer IMPAVIDO to pregnant women. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing IMPAVIDO.  </span> </p>
<p class="Highlighta"><span class="Bold">Advise females of reproductive potential to use effective contraception during therapy and for 5 months after therapy (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>, <a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>, <a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>, <a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>).</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">IMPAVIDO is an antileishmanial drug indicated in adults and adolescents â‰¥12 years of age weighing â‰¥30 kg (66 lbs) for treatment of: </p>
<dl>
<dt>â€¢</dt>
<dd>Visceral leishmaniasis due to <span class="Italics">Leishmania donovani</span> (<a href="#ID_bdddfa36-dd15-437a-add5-ddda07d046f5">1</a>).</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous leishmaniasis</span> due to <span class="Italics">Leishmania braziliensis, Leishmania guyanensis, </span>and <span class="Italics">Leishmania panamensis </span>(<a href="#ID_bdddfa36-dd15-437a-add5-ddda07d046f5">1</a>).</dd>
<dt>â€¢</dt>
<dd>Mucosal leishmaniasis due to <span class="Italics">Leishmania braziliensis </span>(<a href="#ID_bdddfa36-dd15-437a-add5-ddda07d046f5">1</a>).</dd>
</dl>
<p class="Highlighta"><span class="Bold">Limitations of use</span>: <span class="Italics">Leishmania</span> species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same <span class="Italics">Leishmania</span> species to IMPAVIDO (<a href="#ID_bdddfa36-dd15-437a-add5-ddda07d046f5">1</a>, <a href="#ID_42686f96-168f-4cf9-b3fb-5c345089503c">14</a>). The efficacy of IMPAVIDO in the treatment of other <span class="Italics">Leishmania</span> species has not been evaluated. </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Administer with food to ameliorate gastrointestinal adverse reactions.  </p>
<dl>
<dt>â€¢</dt>
<dd>30 to 44 kg:  one 50 mg capsule twice daily for 28 consecutive days (<a href="#ID_a2e45553-d9c7-4bb6-9997-6a45f38d2ffd">2</a>).</dd>
<dt>â€¢</dt>
<dd>45 kg or greater:  one 50 mg capsule three times daily for 28 consecutive days (<a href="#ID_a2e45553-d9c7-4bb6-9997-6a45f38d2ffd">2</a>).</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Each IMPAVIDO capsule for oral use contains 50 mg miltefosine (<a href="#ID_a6e2b1de-ad34-4604-8320-3c1957e7b822">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>,<span class="Bold"></span><a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>, <a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>).</dd>
<dt>â€¢</dt>
<dd>SjÃ¶gren-Larsson-Syndrome (<a href="#ID_4a98f7ff-2cab-4d3e-9d6f-c0e3a511e4a7">4.2</a>, <a href="#ID_d899b562-333d-4202-ab61-8ae62f7770dd">12.3</a>).</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to miltefosine or any of its excipients (<a href="#ID_0563d94c-4f4d-40b0-aebe-5df41aadb684">4.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Embryo-Fetal Toxicity. Do not use in pregnant women. Obtain a urine or serum pregnancy test prior to initiation of therapy. Advise use of effective contraception in females of reproductive potential (<a href="#ID_c76ef055-d392-485b-a069-20aa588290d0">Boxed Warning</a>, <a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>, <a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>, <a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>). </dd>
<dt>â€¢</dt>
<dd>Reproductive effects. Miltefosine caused <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and impaired fertility in male rats and impaired fertility in female rats. Advise patients of reproductive toxicities in animal studies and that the potential effects on human fertility have not been adequately evaluated (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>).</dd>
<dt>â€¢</dt>
<dd>Renal Effects. Monitor serum creatinine during therapy and for 4 weeks after end of therapy (<a href="#ID_699a2f0a-6e89-4fdd-903d-fe8fc08fbbf0">5.3</a>, <a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>).</dd>
<dt>â€¢</dt>
<dd>Hepatic Effects. Monitor transaminases and bilirubin during therapy (<a href="#ID_2c99f89b-5b94-42a9-a32c-8e9d1d424f6a">5.4</a>, <a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>).</dd>
<dt>â€¢</dt>
<dd>Gastrointestinal Effects. Encourage fluid intake (<a href="#ID_7feb30a8-d320-43e6-95db-922daf2c95c8">5.5</a>).</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>. Monitor platelet count during therapy for visceral leishmaniasis (<a href="#ID_c08ef913-8b4d-4893-afe7-8d8cbcc3b50e">5.6</a>, <a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>).</dd>
<dt>â€¢</dt>
<dd>Absorption of Oral Contraceptives. Advise use of alternative method of contraception if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occur (<a href="#ID_9bdb2096-66ea-4b99-bfb3-f34c47dc13ec">5.7</a>). </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. Discontinue IMPAVIDO (<a href="#ID_d788b2e5-153a-493a-87c3-e3713b98cea5">5.8</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Adverse reactions occurring in â‰¥2% of patients include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, elevated transaminases, and elevated creatinine (<a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>).</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact </span><span class="Bold">Paladin Therapeutics Inc. at 1-888-550-6060</span><span class="Bold"> or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>IMPAVIDO did not inhibit human cytochrome P450 enzymes in vitro.</dd>
<dt>â€¢</dt>
<dd>IMPAVIDO did not induce cytochrome 3A activity in rats (<a href="#ID_d158b515-eb81-45fb-a506-a832432fcaba">7</a>, <a href="#ID_d899b562-333d-4202-ab61-8ae62f7770dd">12.3</a>).</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy:  IMPAVIDO should not be used during pregnancy. Obtain a urine or serum pregnancy test in females of reproductive potential prior to prescribing (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>, <a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>, <a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>, <a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>).</dd>
<dt>â€¢</dt>
<dd>Nursing Mothers:  Discontinue drug or nursing depending on importance of drug to mother. Avoid breastfeeding for 5 months after IMPAVIDO therapy (<a href="#ID_247ef062-15b5-4aeb-bf91-d6f612ba9497">8.3</a>).</dd>
<dt>â€¢</dt>
<dd>Females and Males of Reproductive Potential: Advise females to use effective contraception during therapy and for 5 months after therapy. Advise patients of reproductive toxicities in animals, and that the potential for impaired fertility in humans has not been adequately evaluated (<a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>, <a href="#ID_49b34fcc-6afc-41cd-b77e-2c4405babc2c">5.2</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: EMBRYO-FETAL TOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Pregnancy</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 SjÃ¶gren-Larsson-Syndrome</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Reproductive Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Renal Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hepatic Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Gastrointestinal Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Absorption of Oral Contraceptives</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Females and Males of Reproductive Potential</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Treatment of Visceral Leishmaniasis</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Treatment of <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span></a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Treatment of Mucosal Leishmaniasis</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Dosing Instructions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Females and Males of Reproductive Potential</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_c76ef055-d392-485b-a069-20aa588290d0"></a><a name="section-1"></a><p></p>
<h1>WARNING: EMBRYO-FETAL TOXICITY</h1>
<p class="First"><span class="Bold">IMPAVIDO may cause fetal harm. <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">Fetal death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> occurred in animals administered miltefosine at doses lower than the recommended human dose.  Do not administer IMPAVIDO to pregnant women. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing IMPAVIDO. Females of reproductive potential should be advised to use effective contraception during IMPAVIDO therapy and for 5 months after therapy <span class="Italics">[see Contraindications (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>), Warnings and Precautions (<a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>), Use in Specific Populations (<a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>) and Nonclinical Toxicology (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_bdddfa36-dd15-437a-add5-ddda07d046f5"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">IMPAVIDO (miltefosine) capsules are indicated in adults and adolescents â‰¥12 years of age weighing â‰¥ 30 kg for the treatment of:</p>
<dl>
<dt>â€¢</dt>
<dd>Visceral leishmaniasis caused by <span class="Italics">Leishmania donovani [see Clinical Trials (<a href="#ID_70ba89a0-6b57-4e3a-9c2e-3e884fc4c63c">14.1</a>)]</span>. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous leishmaniasis</span> caused by <span class="Italics">Leishmania braziliensis</span>, <span class="Italics">Leishmania guyanensis</span>, and <span class="Italics">Leishmania panamensis [see Clinical Trials (<a href="#ID_7a5425ae-a9cd-4c4d-8a59-a35dbb7fa35b">14.2</a>)]</span>. </dd>
<dt>â€¢</dt>
<dd>Mucosal leishmaniasis caused by <span class="Italics">Leishmania braziliensis [see Clinical Trials (<a href="#ID_3030a523-88b2-42e1-849e-bb90ca5fb552">14.3</a>)]</span>.</dd>
</dl>
<p><span class="Bold">Limitations of Use:<span class="Italics"></span></span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Leishmania</span> species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data <span class="Italics">[see Clinical Trials (<a href="#ID_70ba89a0-6b57-4e3a-9c2e-3e884fc4c63c">14.1</a>, <a href="#ID_7a5425ae-a9cd-4c4d-8a59-a35dbb7fa35b">14.2</a>)]</span>. </dd>
<dt>â€¢</dt>
<dd>There may be geographic variation in clinical response of the same <span class="Italics">Leishmania</span> species to IMPAVIDO <span class="Italics">[see Clinical Trials (<a href="#ID_70ba89a0-6b57-4e3a-9c2e-3e884fc4c63c">14.1</a>, <a href="#ID_7a5425ae-a9cd-4c4d-8a59-a35dbb7fa35b">14.2</a>)]</span>. </dd>
<dt>â€¢</dt>
<dd>The efficacy of IMPAVIDO in the treatment of other <span class="Italics">Leishmania</span> species has not been evaluated. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_a2e45553-d9c7-4bb6-9997-6a45f38d2ffd"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The treatment duration is 28 consecutive days. Administer with food to ameliorate gastrointestinal adverse reactions. </p>
<table>
<caption><span>Table 1: Miltefosine Dosage</span></caption>
<col width="25%">
<col width="74%">
<tbody class="Headless">
<tr class="First">
<td valign="bottom"><p class="First"><span class="Bold">Weight</span></p></td>
<td valign="bottom"><p class="First"><span class="Bold">Dosage and Administration</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">30 kg to 44 kg</p></td>
<td valign="top"><p class="First">One 50 mg capsule twice daily with food (breakfast and dinner) </p></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">45 kg or greater </p></td>
<td valign="top"><p class="First">One 50 mg capsule three times daily with food (breakfast, lunch, and dinner)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_a6e2b1de-ad34-4604-8320-3c1957e7b822"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">IMPAVIDOÂ® (miltefosine) oral capsules are opaque, red, hard gelatin capsules with â€œPLBâ€? imprinted on the capsule body and â€œMILT 50â€? imprinted on the cap using a white ink.  Each capsule contains 50 mg miltefosine <span class="Italics">[see Description (<a href="#ID_d5ab4269-7104-4bda-b6f8-cc52f9965c8c">11</a>), How Supplied/Storage and Handling (<a href="#ID_1dfbaf8a-b5ae-4b35-a39e-6d4dd3f7d9dc">16</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_7c1e4181-6a50-4861-a5ec-934890a978bb"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Pregnancy</h2>
<p class="First">IMPAVIDO may cause fetal harm. IMPAVIDO is contraindicated in pregnant women. Obtain a urine or serum pregnancy test prior to prescribing IMPAVIDO <span class="Italics">[see <a href="#ID_c76ef055-d392-485b-a069-20aa588290d0">Boxed Warning</a> and Use in Specific Populations (<a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4a98f7ff-2cab-4d3e-9d6f-c0e3a511e4a7"></a><a name="section-4.2"></a><p></p>
<h2>4.2 SjÃ¶gren-Larsson-Syndrome</h2>
<p class="First">IMPAVIDO is contraindicated in patients who have SjÃ¶gren-Larsson-Syndrome <span class="Italics">[see Clinical Pharmacology (<a href="#ID_d899b562-333d-4202-ab61-8ae62f7770dd">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0563d94c-4f4d-40b0-aebe-5df41aadb684"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">IMPAVIDO is contraindicated in patients who are hypersensitive to miltefosine or any IMPAVIDO excipients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_b0fbe7a1-fe9b-4990-aee2-10ffe7e07af1"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_757eb80c-8f58-4faa-a568-f08a92d69047"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Embryo-Fetal Toxicity</h2>
<p class="First">Miltefosine may cause fetal harm. Embryo-fetal toxicity, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, was observed in animals administered miltefosine prior to mating, during early pregnancy, and during organogenesis at doses lower than the maximum recommended human dose (MRHD). Do not use IMPAVIDO in pregnant women. Obtain a urine or serum pregnancy test prior to prescribing IMPAVIDO to females of reproductive potential.  Advise females of reproductive potential to use effective contraception during IMPAVIDO therapy and for 5 months after completion of therapy <span class="Italics">[see <a href="#ID_c76ef055-d392-485b-a069-20aa588290d0">Boxed Warning</a>, Contraindications (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>) and Use in Specific Populations (<a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_49b34fcc-6afc-41cd-b77e-2c4405babc2c"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Reproductive Effects</h2>
<p class="First"><span class="Italics">Females</span></p>
<p>Miltefosine caused impaired fertility in rats and reversible follicular atresia and diestrus in dogs at doses approximately 1.0 and 0.2 times respectively the MRHD based on body surface area comparisons <span class="Italics">[see Nonclinical Toxicology (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>)]</span>. Effects on human female fertility have not been formally studied.  </p>
<p><span class="Italics">Males</span></p>
<p>Miltefosine caused reduced viable sperm counts and impaired fertility in rats at doses approximately 0.4 times the MRHD <span class="Italics">[see Nonclinical Toxicology (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a></span>)<span class="Italics">]</span>. A higher dose in rats, approximately 1.0 times the MRHD, caused <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and impaired fertility that did not fully reverse 10 weeks after drug administration ended.</p>
<p><span class="product-label-link" type="condition" conceptid="4071874" conceptname="Pain in scrotum">Scrotal pain</span> and decreased or absent ejaculation during therapy have been reported during IMPAVIDO therapy <span class="Italics">[see Adverse Reactions (<a href="#ID_5b1ad54c-31bf-43df-8f55-1dcc3f1bcbb8">6.2</a></span>)<span class="Italics">]</span>. The effects of IMPAVIDO on human male fertility have not been adequately studied.</p>
<p>Advise women and men of the animal fertility findings, and that the potential for impaired fertility with IMPAVIDO therapy in humans has not been adequately evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_699a2f0a-6e89-4fdd-903d-fe8fc08fbbf0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Renal Effects</h2>
<p class="First">Elevations of serum creatinine (Cr) were noted in clinical trials evaluating IMPAVIDO in the treatment of cutaneous, mucosal and visceral leishmaniasis.  Monitor renal function weekly in patients receiving IMPAVIDO during therapy and for 4 weeks after end of therapy <span class="Italics">[see Adverse Reactions (<a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2c99f89b-5b94-42a9-a32c-8e9d1d424f6a"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hepatic Effects</h2>
<p class="First">Elevations in liver transaminases (ALT, AST) and bilirubin were noted in clinical trials evaluating IMPAVIDO in the treatment of visceral leishmaniasis. Monitor liver transaminases (ALT, AST) and bilirubin during therapy in patients receiving IMPAVIDO <span class="Italics">[see Adverse Reactions (<a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7feb30a8-d320-43e6-95db-922daf2c95c8"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Gastrointestinal Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> commonly occur during IMPAVIDO administration and may result in <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>. Encourage fluid intake to avoid <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> <span class="Italics">[see Adverse Reactions (<a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c08ef913-8b4d-4893-afe7-8d8cbcc3b50e"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> during therapy has been reported in patients treated for visceral leishmaniasis. Monitor platelet count during therapy for visceral leishmaniasis <span class="Italics">[see Adverse Reactions (<a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>, <a href="#ID_5b1ad54c-31bf-43df-8f55-1dcc3f1bcbb8">6.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9bdb2096-66ea-4b99-bfb3-f34c47dc13ec"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Absorption of Oral Contraceptives</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurring during IMPAVIDO therapy may affect the absorption of oral contraceptives, and therefore compromise their efficacy.  If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occur during IMPAVIDO therapy, advise females to use additional non-hormonal or alternative method(s) of effective contraception.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d788b2e5-153a-493a-87c3-e3713b98cea5"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> has been reported during IMPAVIDO therapy. Discontinue IMPAVIDO if an exfoliative or <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous rash</span> is noted during therapy <span class="Italics">[see Adverse Reactions (<a href="#ID_5dd633ee-8477-46c2-bb9c-3643363960db">6.1</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_bff264c3-9ed9-45dd-8a75-1e7b518159ad"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5dd633ee-8477-46c2-bb9c-3643363960db"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Bold">Visceral Leishmaniasis</span></p>
<p>One Phase 3 trial was conducted in patients â‰¥ 12 years of age in India. Two-hundred and ninety-nine (299) patients (211 men and 88 women) received oral IMPAVIDO at a target dose of 2.5 mg/kg/day for 28 days (50 mg capsule once daily if weight was less than 25 kg and 50 mg capsule twice daily if weight was 25 kg or greater).  Patients ranged between 12 and 64 years of age. Weight ranged between 15 and 67 kg (mean weight 38.6 kg) and BMI ranged between 8.2 and 24 (mean 16.1). Ninety-nine (99) patients received 1 mg/kg/day amphotericin B deoxycholate intravenously every other day for 15 doses.  A statistically significant higher percentage of men received IMPAVIDO compared to amphotericin B. </p>
<p>Less than 1% of patients who received IMPAVIDO died (2/299) and no patient who received amphotericin B died.  Serious adverse reactions were reported in 2% of IMPAVIDO recipients (6/299) and 1% of amphotericin B recipients (1/99). Approximately 3% of patients discontinued treatment in each treatment arm due to an adverse reaction. Serious adverse reactions and adverse reactions leading to drug discontinuation that were thought to be related or possibly related to IMPAVIDO included <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, CTCAE<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> Grade 4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (â‰¥10 stools per day) and CTCAE Grade 4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> (â‰¥10x upper limit of normal ULN). </p>
<table>
<caption><span>Table 2: Treatment Emergent Adverse Reactions Occurring in â‰¥2% of Visceral Leishmaniasis Patients Receiving IMPAVIDO</span></caption>
<col width="53%">
<col width="28%">
<col width="35%">
<tbody class="Headless">
<tr class="First">
<td valign="middle"><p class="First"><span class="Bold">System Organ Class<br>Preferred Term</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">IMPAVIDO<br>N = 299</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">Amphotericin B Deoxycholate<br>N = 99</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td valign="middle"></td>
<td valign="middle"></td>
</tr>
<tr>
<td valign="middle"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="middle"><p class="First">61 (20.4%)</p></td>
<td align="center" valign="middle"><p class="First">6 (6.1%)</p></td>
</tr>
<tr>
<td valign="middle"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center" valign="middle"><p class="First">113 (37.8%)</p></td>
<td align="center" valign="middle"><p class="First">20 (20.0%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">General Disorders</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
</tr>
<tr>
<td valign="middle"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="center" valign="middle"><p class="First">19 (6.3%)</p></td>
<td align="center" valign="middle"><p class="First">4 (4.0%)</p></td>
</tr>
<tr>
<td valign="middle"><p class="First">Metabolism and Nutrition Disorders</p></td>
<td valign="middle"></td>
<td valign="middle"></td>
</tr>
<tr class="Last">
<td valign="middle"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td align="center" valign="middle"><p class="First">69 (23.1%)</p></td>
<td align="center" valign="middle"><p class="First">22 (22.2%)</p></td>
</tr>
</tbody>
</table>
<p>In this study, creatinine (Cr) elevations â‰¥ 1.5 times above baseline occurred in approximately 10% of IMPAVIDO recipients and in 40% of amphotericin B recipients at the end of therapy. Ten percent of subjects in each arm had Cr elevations â‰¥1.5 times above baseline at 6 months follow up. No IMPAVIDO recipient discontinued therapy due to Cr elevation.</p>
<p>Elevations of transaminases during therapy occurred in up to half of IMPAVIDO recipients and up to a third of amphotericin B recipients. The elevations were mild (&lt; 3x ULN) or moderate (3-5x ULN) in 94% and 6% respectively of IMPAVIDO-treated patients who experienced an elevation. No patient discontinued therapy due to elevations in transaminases. </p>
<p>At the end of therapy, 62% and 2.4% of IMPAVIDO recipients and 54% and 2% of amphotericin B recipients had platelet count &lt; 150,000 and &lt; 50,000 respectively. </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span></span></p>
<p>The efficacy of IMPAVIDO in the treatment of <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">cutaneous leishmaniasis</span> was evaluated in one placebo-controlled trial conducted in Colombia and Guatemala and in two comparative trials conducted in Bolivia and Brazil respectively. In the placebo-controlled trial, eighty-nine (89) patients â‰¥12 years of age received a target IMPAVIDO dose of 2.5 mg/kg/day for 28 days and  forty-four (44) received placebo. In the comparative trials, one hundred and twenty (120) patients â‰¥12 years of age received a target IMPAVIDO dose of 2.5 mg/kg/day for 28 days and fifty eight (58) patients received 20 mg/kg/day pentavalent antimony (meglumine) parenterally for 20 days.</p>
<table>
<caption><span>Table 3: Adverse Reactions Occurring in â‰¥2% of IMPAVIDO-Treated Patients â‰¥12 Years of Age with <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span> in the Placebo-Controlled Trial</span></caption>
<col width="57%">
<col width="31%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><p class="First"><span class="Bold">System Organ Class<br>Preferred Term</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">IMPAVIDO<br>N = 89</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">Placebo<br>N = 44</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First">Ear and Labyrinth Disorders</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="30284" conceptname="Motion sickness">Motion Sickness</span></p></td>
<td align="center" valign="middle"><p class="First">26 (29.2%)</p></td>
<td align="center" valign="middle"><p class="First">10 (22.7%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td align="center" valign="middle"><p class="First">10 (11.2%)</p></td>
<td align="center" valign="middle"><p class="First">3 (6.8%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="middle"><p class="First">7 (7.9%)</p></td>
<td align="center" valign="middle"><p class="First">2 (4.5%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="middle"><p class="First">32 (35.9%)</p></td>
<td align="center" valign="middle"><p class="First">5 (11.1%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center" valign="middle"><p class="First">4 (4.5%)</p></td>
<td align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td valign="top"><p class="First">General and Administration Site Disorders</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td align="center" valign="top"><p class="First">3 (3.4%)</p></td>
<td align="center" valign="top"><p class="First">1 (2.3%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td align="center" valign="top"><p class="First">5 (5.6%)</p></td>
<td align="center" valign="top"><p class="First">2 (4.5%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center" valign="top"><p class="First">4 (4.5%)</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center" valign="top"><p class="First">25 (28.1%)</p></td>
<td align="center" valign="top"><p class="First">10 (22.7%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td align="center" valign="top"><p class="First">3 (3.4%)</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Skin and Subcutaneous Tissue Disorders</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td align="center" valign="top"><p class="First">4 (4.5%)</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<table>
<caption><span>Table 4: Adverse Reactions Occurring in â‰¥2% of IMPAVIDO-Treated Patients â‰¥ 12 Years of Age with <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span> in Two Comparative Trials</span></caption>
<col width="57%">
<col width="31%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td valign="top"><p class="First"><span class="Bold">System Organ Class<br>Preferred Term</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">IMPAVIDO<br>N = 120</span></p></td>
<td align="center" valign="middle"><p class="First"><span class="Bold">Meglumine<br>N = 58</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td align="center" valign="middle"><p class="First">9 (7.5%)</p></td>
<td align="center" valign="middle"><p class="First">3 (5.2%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="middle"><p class="First">18 (15.0%)</p></td>
<td align="center" valign="middle"><p class="First">3 (5.2%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="middle"><p class="First">50 (41.7%)</p></td>
<td align="center" valign="middle"><p class="First">3 (5.2%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="center" valign="middle"><p class="First">33 (27.5%)</p></td>
<td align="center" valign="middle"><p class="First">0</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="439840" conceptname="Lymphangitis">Lymphangitis</span></p></td>
<td align="center" valign="top"><p class="First">7 (5.8%)</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Metabolism and Nutrition Disorders</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased Appetite</span></p></td>
<td align="center" valign="top"><p class="First">13 (10.8%)</p></td>
<td align="center" valign="top"><p class="First">4 (5.8%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center" valign="top"><p class="First">15 (12.5%)</p></td>
<td align="center" valign="top"><p class="First">4 (6.9%)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Skin and Subcutaneous Tissue Disorders</p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td align="center" valign="top"><p class="First">7 (5.8%)</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>In the placebo controlled trial, 12/89 (13.4%) IMPAVIDO subjects had Cr increases of 1.5-3 times above baseline, compared to 2/44 (4.5%) placebo subjects at end of therapy. In the comparative trial, a similar percentage of subjects who received IMPAVIDO or pentavalent antimony had Cr elevations above baseline at 3 and 6 months after therapy (approximately 5%). Approximately 25% of IMPAVIDO subjects and 11% of pentavalent antimony subjects had Cr elevations 1.5-3 times above baseline at the end of therapy in the two active controlled trials.  The frequency of AST and ALT increase above upper limit of normal at end of therapy was similar in IMPAVIDO and placebo recipients (approximately 5%). </p>
<p>Other adverse events seen at &lt;2% incidence in the IMPAVIDO group included <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="4311823" conceptname="Ecthyma">ecthyma</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">testicular pain</span>, <span class="product-label-link" type="condition" conceptid="4339088" conceptname="Testicular mass">testicular swelling</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133547" conceptname="Pyoderma">pyoderma</span>.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd> Common Terminology Criteria for Adverse Events</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5b1ad54c-31bf-43df-8f55-1dcc3f1bcbb8"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during use of IMPAVIDO worldwide.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Blood and Lymphatics Disorders</span>: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> </p>
<p><span class="Italics">General Disorders</span>: <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> </p>
<p><span class="Italics">Hepatobiliary Disorders</span>: <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> </p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="4071874" conceptname="Pain in scrotum">scrotal pain</span>, decreased ejaculate volume, absent ejaculation. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span>: <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_d158b515-eb81-45fb-a506-a832432fcaba"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vitro</span> and animal metabolism studies showed that miltefosine did not markedly induce or inhibit the activity of the major human cytochrome P450 enzymes <span class="Italics">[see Clinical Pharmacology (<a href="#ID_d899b562-333d-4202-ab61-8ae62f7770dd">12.3</a>)]</span>.  The potential of miltefosine to interact with drug transporters has not been evaluated.  </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_a4829048-d05c-47e7-b8ea-88fc3e72afc0"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D </p>
<p><span class="Italics">Risk Summary</span></p>
<p>IMPAVIDO may cause fetal harm. Human pregnancy data are not available, however, embryo-fetal toxicity including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, was observed in embryo-fetal studies in rats and rabbits administered oral miltefosine during organogenesis at doses that were respectively 0.06 and 0.2 times the maximum recommended human dose (MRHD), based on body surface area (BSA) comparison. Numerous visceral and skeletal <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> were observed in a fertility study in female rats administered miltefosine prior to mating through day 7 of pregnancy at doses 0.3 times the MRHD.  Do not administer IMPAVIDO to pregnant women. </p>
<p><span class="Italics">Clinical Considerations</span></p>
<p>During pregnancy, visceral leishmaniasis may be life-threatening for the mother and may result in adverse fetal outcomes, including <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>, congenital disease due to vertical transmission, <span class="product-label-link" type="condition" conceptid="72726" conceptname="Light-for-dates with signs of fetal malnutrition">small for gestational age</span> newborn, and severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.  During pregnancy, <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">cutaneous leishmaniasis</span> may manifest with larger and atypical appearing lesions and may be associated with increased risk for adverse fetal outcomes, including preterm births and <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span>.</p>
<p><span class="Italics">Animal Data</span></p>
<p>Miltefosine administration in rat embryo-fetal toxicity studies during early embryonic development (Day 6 to Day 15 of gestation) caused embryo-fetal toxicity including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at dosages of â‰¥ 1.2 mg/kg/day (0.06 times the MRHD based on BSA comparison). Teratogenic effects included undeveloped cerebrum, hemorrhagic fluid filling the lumina of the skull, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>.  Embryo-fetal toxicity was also observed in rabbits after oral administration of miltefosine during organogenesis (Day 6 to Day 18 of gestation) at doses â‰¥ 2.4 mg/kg/day (0.2 times the MRHD based on BSA comparison). In both rats and rabbits, there were no viable litters at miltefosine doses â‰¥ 6.0 mg/kg/day (0.3 or 0.6 times the MRHD based on BSA comparisons for rats and rabbits respectively). </p>
<p>In a separate female fertility study in rats, miltefosine doses â‰¥ 6.81 mg/kg/day (0.3 times the MRHD based on BSA comparison) administered for four weeks before mating and up to Day 7 of pregnancy produced numerous visceral (misshapen cerebral structures, dilated ventricles filled with brown <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span>, misshapen spinal cord, misshapen and malpositioned eyes, hypophysis, and absent inner ear) and skeletal (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, dumbbell-shaped ossification of thoracic vertebral centers, markedly enlarged skull bones, and markedly dilated suturae) <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. <span class="Italics">[see Contraindications (<a href="#ID_7afff8ae-dde3-4ab4-a3ea-ee6f6a72677e">4.1</a>), Nonclinical Toxicology (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>)]</span>.  </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_247ef062-15b5-4aeb-bf91-d6f612ba9497"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether IMPAVIDO is present in human milk.  Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from IMPAVIDO, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Breastfeeding should be avoided for 5 months after IMPAVIDO therapy.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_9b9dccba-6011-4d67-a0dc-2f0381317f7d"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients &lt; 12 years have not been established. Juvenile rats were more sensitive to the miltefosine-induced effects, especially retinal and kidney effects, than adult rats <span class="Italics">[see Indications and Usage (<a href="#ID_bdddfa36-dd15-437a-add5-ddda07d046f5">1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_14ac402d-e026-4d55-a49a-0fd9f693255c"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of IMPAVIDO did not include sufficient numbers of subjects 65 years of age and over to determine if they respond differently than younger subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6316dfd9-473b-43f6-93bb-e35744ea9d23"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Patients with serum creatinine or BUN levels â‰¥1.5 times the upper limit of normal were excluded from the clinical studies.  Miltefosine pharmacokinetics have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75df88ba-a2d4-4b41-9811-214fab67d834"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Patients with serum levels of ALT or AST â‰¥3 times the upper limit of normal and bilirubin levels â‰¥2 times the upper limit of normal were excluded from the clinical studies. Miltefosine pharmacokinetics have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Females and Males of Reproductive Potential</h2>
<p class="First"><span class="Italics">Contraception</span></p>
<p>IMPAVIDO may cause fetal harm when used during pregnancy.  Advise females of reproductive potential to use effective contraception during IMPAVIDO therapy and for 5 months after therapy is completed <span class="Italics">[see <a href="#ID_c76ef055-d392-485b-a069-20aa588290d0">Boxed Warning</a>, Warnings and Precautions (<a href="#ID_757eb80c-8f58-4faa-a568-f08a92d69047">5.1</a>) and Use in Specific Populations (<a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>)]</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurring during IMPAVIDO therapy may affect absorption of oral contraceptives and therefore may compromise their efficacy. Advise females who use oral contraceptives to use additional non-hormonal or alternative method(s) of effective contraception during IMPAVIDO therapy if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs during therapy <span class="Italics">[see Warnings and Precautions (<a href="#ID_9bdb2096-66ea-4b99-bfb3-f34c47dc13ec">5.7</a>)]</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<p><span class="Underline">Females</span></p>
<p>Miltefosine caused impaired fertility in rats and caused reversible follicular atresia and diestrus in dogs at doses approximately 1.0 and 0.2 times respectively the MRHD <span class="Italics">[see Warnings and Precautions (<a href="#ID_49b34fcc-6afc-41cd-b77e-2c4405babc2c">5.2</a>), Nonclinical Toxicology (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>)]</span>. The effects of IMPAVIDO on human female fertility have not been formally studied. </p>
<p><span class="Underline">Males</span></p>
<p>Miltefosine caused reduced viable sperm counts and impaired fertility in rats at doses approximately 0.4 times the MRHD <span class="Italics">[see Warnings and Precautions (<a href="#ID_49b34fcc-6afc-41cd-b77e-2c4405babc2c">5.2</a>), Nonclinical Toxicology (<a href="#ID_27039460-3945-426c-9ade-847613faa3f7">13.1</a>)]</span>. A higher dose in rats, approximately 1.0 times the MRHD, caused <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> and impaired fertility that did not fully reverse 10 weeks after drug administration ended. The effects of IMPAVIDO on human male fertility have not been adequately studied. </p>
<p>Advise women and men of the animal fertility findings, and that the potential for impaired fertility with IMPAVIDO therapy has not been adequately evaluated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_16ad4fe5-5e59-4276-950b-85411862a545"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The common adverse effects of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> are likely in case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Institute adequate hydration to prevent the risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, and replace electrolytes as necessary.  Because miltefosine is only slightly excreted in the urine, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> will not increase miltefosine excretion. Gastrointestinal lavage is of unknown value. A specific antidote to treat miltefosine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is not known. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_d5ab4269-7104-4bda-b6f8-cc52f9965c8c"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">IMPAVIDO capsules contain the active ingredient miltefosine, an antileishmanial agent.  The chemical name of miltefosine is 2-[[(hexadecyloxy)hydroxyphosphenyl]oxy]-N,N,N-trimethylethylammonium inner salt.  Miltefosine is a white powder that is freely soluble in water, 0.1 N HCl or NaOH, methanol, and ethanol.  It has the empirical formula of C<span class="Sub">21</span>H<span class="Sub">46</span>NO<span class="Sub">4</span>P with a molecular weight of 407.6 and the following structural formula:</p>
<div class="Figure">
<a name="id1747838128"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5&amp;name=d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5-01.jpg">
</div>
<p>The inactive ingredients are colloidal silicon dioxide, microcrystalline cellulose, lactose monohydrate, talc, and magnesium stearate.  The capsule shell contains gelatin, titanium dioxide, ferric oxide, and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_3d51b9af-22a6-4251-a636-4e039063a9e9"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_e32b46d3-8f1e-41e6-a5f4-dc3aeb6887dc"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Miltefosine is an anti-leishmanial agent <span class="Italics">[see Clinical Pharmacology (<a href="#ID_cdf79ff8-be68-44c9-a086-2791965525db">12.4</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_d899b562-333d-4202-ab61-8ae62f7770dd"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic parameters of miltefosine in patients with visceral and <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">cutaneous leishmaniasis</span> treated for 28 days with IMPAVIDO are listed in Table 5. Due to the long half-life of miltefosine (&gt; 6 days), trough plasma concentrations did not appear to reach a steady state at the end of treatment (i.e., Day 28). </p>
<table>
<caption><span>Table 5: Mean (%CV) Pharmacokinetic Parameters for Miltefosine Following Oral Capsule Administration to Adult Patients with Visceral and <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span></span></caption>
<col width="18%">
<col width="23%">
<col width="12%">
<col width="12%">
<col width="15%">
<col width="9%">
<col width="11%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">a: Adolescent (â‰¥12 years)/Adults, mean dose per kg was 3.1 mg/kg/day<br>b: Adolescent (â‰¥12 years)/Adults, mean dose per kg was 3.6 mg/kg/day<br>c: Adults, mean dose per kg was 1.8 mg/kg/day<br>d: median (range)<br>e: AUC<span class="Sub">0-12h</span> for BID, AUC<span class="Sub">0-8h</span> for TID<br>f: t<span class="Sub">1/2,</span>Î± = distribution phase half-life; t<span class="Sub">1/2,Î²</span> = terminal elimination phase half-life<br>g: Estimates based on a population PK model<br>h: mean (% standard error)</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td valign="bottom"></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">Dose</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">C<span class="Sub">max</span><br>(Âµg/mL)</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">T<span class="Sub">max</span><span class="Sup">d</span><br>(hr)</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">AUC<span class="Sub">tau</span><span class="Sup">e</span><br>(Âµgâˆ™hr/mL)</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">t<span class="Sub">1/2,Î±</span><span class="Sup">f</span><br>(day)</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">t<span class="Sub">1/2,Î²</span><span class="Sup">g</span><br>(day)</span></p></td>
</tr>
<tr>
<td align="center" rowspan="2" valign="top"><p class="First">Visceral Leishmaniasis<br>(on Day 23)</p></td>
<td align="center" valign="top"><p class="First">50 mg BID (4 wks)<span class="Sup">a</span></p></td>
<td align="center" valign="top"><p class="First">66.2 (28.5)</p></td>
<td align="center" valign="top"><p class="First">7(2-12)</p></td>
<td align="center" valign="top"><p class="First">636 (26.7)</p></td>
<td align="center" valign="top"><p class="First">6.4 (31.1)</p></td>
<td valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">50 mg BID (1 wk)/<br>50 mg TID (3 wks)<span class="Sup">b</span></p></td>
<td align="center" valign="top"><p class="First">75.9 (17.6)</p></td>
<td align="center" valign="top"><p class="First">4 (2-8)</p></td>
<td align="center" valign="top"><p class="First">486 (18.1)</p></td>
<td align="center" valign="top"><p class="First">8.5 (28.9)</p></td>
<td valign="top"></td>
</tr>
<tr class="Last">
<td align="center" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span><span class="Sup">c</span><br>(on Day 27)</p></td>
<td align="center" valign="top"><p class="First">50 mg TID (4 wks)</p></td>
<td align="center" valign="top"><p class="First">37.3 (22)<span class="Sup">f</span></p></td>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">295 (22)<span class="Sup">f</span></p></td>
<td align="center" valign="top"><p class="First">6.8 (5.8)<span class="Sup">g,h</span></p></td>
<td align="center" valign="top"><p class="First">30.7 (18.3)<span class="Sup">g,h</span></p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Absorption </span></p>
<p>Absolute bioavailability of miltefosine has not been determined. In patients with visceral leishmaniasis, maximum miltefosine concentrations following oral administration of IMPAVIDO capsules were reached right before the next dose in many patients, indicating that the absorption of miltefosine may proceed throughout the dosing interval.</p>
<p><span class="Bold">Distribution</span></p>
<p>The distribution of miltefosine has not been studied in humans. Human plasma protein binding of miltefosine, evaluated by an ultracentrifugation method, was 98% over the drug concentration range from 0.1 to 10 Âµg/mL. In rats, radioactivity of [<span class="Sup">14</span>C] miltefosine is widely distributed after both single and repeated oral administration with highest uptake of radioactivity in kidney, liver, and spleen.  Placental transfer and excretion into milk have not been investigated.  </p>
<p><span class="Bold">Metabolism and Excretion</span></p>
<p>No <span class="Italics">in vitro</span> oxidative metabolism by 15 different human cytochrome P450 enzymes (1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, 3A5, 3A7, and 4A1) was observed. </p>
<p>A slow metabolic breakdown could be shown in human hepatocytes, resulting in the release of choline by phospholipase D-like cleavage of the miltefosine molecule.  The fatty alcohol-containing fragment of miltefosine can enter the metabolism of fatty acids after being oxidized to palmitic acid.  This oxidation is blocked in patients with SjÃ¶gren-Larsson syndrome, which is caused by a genetic defect in fatty aldehyde dehydrogenase activity.  IMPAVIDO is contraindicated in patients who have SjÃ¶gren-Larsson-Syndrome <span class="Italics">[see Contraindications (<a href="#ID_4a98f7ff-2cab-4d3e-9d6f-c0e3a511e4a7">4.2</a>)]</span>.</p>
<p>There was little or no evidence of time or metabolism dependent inhibition of the cytochrome P450 enzymes examined at up to approximately 40 Âµg/mL miltefosine.  </p>
<p>Oral administration of miltefosine did not markedly induce the content of hepatic CYP3A assayed by demethylation activity of erythromycin in rats.</p>
<p>In visceral leishmaniasis patients, &lt;0.2% of the administered dose was excreted into the urine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cdf79ff8-be68-44c9-a086-2791965525db"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>The specific mode of action of miltefosine against <span class="Italics">Leishmania</span> species is unknown.  The mechanism of action of miltefosine is likely to involve interaction with lipids (phospholipids and sterols), including membrane lipids, inhibition of cytochrome c oxidase (mitochondrial function), and <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>-like <span class="product-label-link" type="condition" conceptid="4034461" conceptname="Cytolysis">cell death</span>.</p>
<p><span class="Bold">Activity <span class="Italics">In Vitro</span> and <span class="Italics">In Vivo</span></span></p>
<p>Miltefosine has anti-leishmanial activity <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see Clinical Studies (<a href="#ID_42686f96-168f-4cf9-b3fb-5c345089503c">14</a>)]</span>. Sensitivity of different <span class="Italics">Leishmania</span> species as well as different <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of a <span class="Italics">Leishmania</span> species to miltefosine may vary in different geographic regions.<span class="Italics"></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span> </span></p>
<p><span class="Italics">In vitro</span> studies show a potential for development of resistance to miltefosine. Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of<span class="Italics"> L. braziliensis </span>with intrinsic resistance to miltefosine have been identified<span class="Italics">. </span> However, the clinical relevance of these observations is not known.</p>
<p><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug resistance</span> could be due to a decrease in miltefosine accumulation within <span class="Italics">Leishmania</span> parasite which is thought to be due to either an increase in drug efflux, mediated by the overexpression of the ABC transporter P-glycoprotein and/or a decrease in drug uptake by the inactivation of the miltefosine transport machinery that consists of the miltefosine transporter and its beta subunit. Mutation in the transporter gene was reported in the isolates from a relapsed patient in one study. However, the clinical relevance of these findings is not known. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_30c6d008-f4ea-4646-b5e1-09c7a399bec2"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_27039460-3945-426c-9ade-847613faa3f7"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Mutagenicity/Carcinogenicity: Miltefosine tested negative in the AMES-<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> test, DNA-amplification test, chromosomal aberration test <span class="Italics">in vitro</span>, UDS-test <span class="Italics">in vivo/in vitro</span>, and oral mouse micronucleus test <span class="Italics">in vivo</span>.  The V 79 mammalian cell HPRT gene mutation test showed an increase in mutant frequency without dose dependency.  In view of all mutagenicity test results, the single positive finding in the V 79 HPRT test is considered to be not of toxicological relevance with respect to a mutagenic risk to humans.</p>
<p>Carcinogenicity studies were not performed.  In a 52-week oral rat toxicity study, testicular Leydig cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span> was observed in 3Â of 30Â male rats with daily administration of 21.5Â mg/kg/day miltefosine (1.0 times the MRHD based on BSA comparison).  The carcinogenic potential of miltefosine in humans is unknown.</p>
<p>In a Segment I fertility study in male rats, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, reduced numbers of viable sperm, and impaired fertility were observed in rats following daily oral doses of â‰¥ 8.25 mg/kg (0.4 times the MRHD based on BSA comparison).  These findings were reversible within a recovery period of 10 weeks except at the highest dose tested, 21.5 mg/kg/day (1.0 times the MRHD based on BSA comparison), where effects were not fully reversible.  </p>
<p>In a female fertility study in rats, estrus cycle arrest in the metestrus or diestrus phases occurred with the high-dose of 21.5 mg/kg (1.0 times the MRHD based on BSA comparison). At doses of 6.81 and 21.5 mg/kg (0.3 and 1.0 times the MRHD respectively based on BSA comparison) increased numbers of embryonic and fetal resorptions and dead fetuses were observed. In a 52-week toxicology study in dogs, increased numbers of atretic follicles in the ovaries, and cycle arrest in the uterus, vagina, and mammary gland with morphology consistent with anestrus or diestrus was observed at doses â‰¥ 1 mg/kg/day (0.2 times the MRHD based on BSA comparison). The effects in dogs were fully reversible after a recovery period of 6 weeks.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_cf4770e4-336e-476b-93dc-850837751f50"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Toxicological studies with miltefosine have been performed in mice, rats, dogs, and rabbits.  Adverse reactions not observed in clinical studies but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: </p>
<p>Acute and chronic toxicity:  The oral administration of miltefosine in rats was associated with lesions affecting the eyes (<span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span>). <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">Retinal degeneration</span> was observed after 8-weeks treatment at doses of 10 mg/kg/day (0.5 times the MRHD based on BSA comparison).  Juvenile rats were more sensitive to the miltefosine-induced effects, especially on eyes and kidneys, than adult rats with <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span> occurring at doses â‰¥ 2.15 mg/kg/day (0.1 times the MRHD based on BSA comparison), and reversible damage to proximal tubule epithelium occurring at doses â‰¥ 4.64 mg/kg/day (0.2 times the MRHD based on BSA comparison).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_42686f96-168f-4cf9-b3fb-5c345089503c"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_70ba89a0-6b57-4e3a-9c2e-3e884fc4c63c"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Treatment of Visceral Leishmaniasis</h2>
<p class="First">One randomized, open-label, active-controlled study was conducted to evaluate the efficacy of IMPAVIDO in the treatment of visceral leishmaniasis in Bihar, India, an area where <span class="Italics">L. donovani</span> is known epidemiologically to be the prevalent infecting species. Patients â‰¥ 12 years of age with clinical signs and symptoms compatible with visceral leishmaniasis (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, and <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span>) confirmed by the presence of <span class="Italics">Leishmania</span> amastigotes in aspirates of spleen or bone marrow were randomized to receive oral IMPAVIDO or intravenous amphotericin B deoxycholate in a 3:1 ratio.  Patients weighing â‰¥ 25 kg received an IMPAVIDO 50 mg capsule with meals twice a day.  Patients weighing &lt; 25 kg received an IMPAVIDO 50 mg capsule with meals once a day in the morning. Weight ranged between 15 and 67 kg (mean weight 38.6 kg) and BMI ranged between 8.2 and 24 (mean 16.1). No patient weighed more than 70kg. Amphotericin B was administered intravenously over 6 continuous hours at 1 mg/kg every other day for 15 doses. Patients were hospitalized for the duration of therapy. </p>
<p>Exclusion criteria included platelet count &lt;50 Ã— 10<span class="Sup">9</span>/L, white cell count &lt;1 Ã— 10<span class="Sup">9</span>/L, hemoglobin &lt;6 g/100 mL, AST or ALT â‰¥3 times upper limit of the normal range, bilirubin â‰¥2 times upper limit of the normal range, serum creatinine or BUN &gt;1.5 times upper limit of the normal range, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time &gt;5Â seconds above control, and any non-compensated or uncontrolled condition including human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  Women of reproductive potential were required to use effective contraception for the duration of therapy and for 2 months post therapy.</p>
<p>Final cure was defined as initial cure at end of therapy plus absence of signs and symptoms of visceral leishmaniasis at 6 months follow up. Initial cure at the end of therapy was evaluated by repeat spleen or bone marrow <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>.  Patients with initial parasitologic cure were followed for 6 months; patients without absence of clinical signs and symptoms of visceral leishmaniasis were to be evaluated with repeat spleen or bone marrow <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> to determine final cure. </p>
<p>Two hundred and ninety nine (299) patients received IMPAVIDO and 99 patients received amphotericin B.  Approximately, 70% of patients in each arm had previously failed treatment with pentavalent antimony.  Initial cure was achieved in 98% of patients in each treatment arm. At 6 months after therapy, 88 (29.5%) IMPAVIDO recipients and 12 (12.1%) amphotericin B recipients continued to have signs and symptoms suggestive of visceral leishmaniasis. These signs or symptoms were attributed to alternative diagnosis in 73 patients. The remaining 27 patients, all in the IMPAVIDO arm, underwent evaluation with splenic or bone marrow <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, and 9 (3.0%) were positive for <span class="Italics">Leishmania</span> amastigotes, indicating relapse.  The final cure rates for IMPAVIDO and amphotericin B were 94% and 97%, respectively.  </p>
<table>
<caption><span>Table 6: Efficacy of IMPAVIDO in Visceral Leishmaniasis in Patients â‰¥12 years of Age in India</span></caption>
<col width="21%">
<col width="32%">
<col width="40%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>The 95% exact confidence interval for the difference (IV Amphotericin B â€“ IMPAVIDO) in final cure is (-3.0%, 6.8%).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td valign="bottom"></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">IMPAVIDO<br>N = 299</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">Amphotericin B Deoxycholate<br>N = 99</span></p></td>
</tr>
<tr><td align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">End of therapy</span></p></td></tr>
<tr>
<td valign="bottom"><p class="First">Initial Cure</p></td>
<td align="center" valign="bottom"><p class="First">293 (98%)</p></td>
<td align="center" valign="bottom"><p class="First">97 (98%)</p></td>
</tr>
<tr><td align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">6 months after therapy</span></p></td></tr>
<tr>
<td valign="bottom"><p class="First">Final Cure<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td align="center" valign="bottom"><p class="First">282 (94%)</p></td>
<td align="center" valign="bottom"><p class="First">96 (97%)</p></td>
</tr>
<tr>
<td valign="bottom"><p class="First">Treatment Failure  </p></td>
<td align="center" valign="bottom"><p class="First">9 (3%)</p></td>
<td align="center" valign="bottom"><p class="First">0 (0)</p></td>
</tr>
<tr class="Last">
<td valign="bottom"><p class="First">Not Assessable  </p></td>
<td align="center" valign="bottom"><p class="First">8 (3%)</p></td>
<td align="center" valign="bottom"><p class="First">3 (3%)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7a5425ae-a9cd-4c4d-8a59-a35dbb7fa35b"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Treatment of <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span></h2>
<p class="First">A placebo controlled study was performed in Colombia where <span class="Italics">L. panamensis</span> and <span class="Italics">L. braziliensis</span> are epidemiologically known to be the prevalent infecting <span class="Italics">Leishmania</span> species, and in Guatemala where <span class="Italics">L. braziliensis</span> is epidemiologically known to be the prevalent infecting species.  The study included male and female patients older than 12 years of age who had newly diagnosed or relapsing <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">cutaneous leishmaniasis</span> without mucosal involvement, parasitologically confirmed, presenting with at least one <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span> with minimum area of 50 mm<span class="Sup">2</span>.  Exclusion criteria were AST or ALT â‰¥2 times upper limit of normal range, bilirubin â‰¥1.5 times upper limit of normal range, and serum creatinine or BUN &gt;1.5 times upper limit of normal range. Women of reproductive potential were required to use effective contraception for the duration of therapy and for 2 months post therapy. </p>
<p>Patients were randomized to receive IMPAVIDO or placebo in a 2:1 allocation. Patients who weighed &lt; 45 kg received IMPAVIDO 50 mg capsule twice a day, and patients who weighed â‰¥45 kg received IMPAVIDO 50 mg capsule three times a day.  No patient weighed more than 84 kg. Definite cure was defined as apparent (complete epithelialization of all lesions) or partial cure (incomplete epithelialization, no enlargement by &gt; 50% in lesions, no appearance of new lesions, and negative parasitology if done) at 2 weeks after end of therapy and complete epithelialization of all <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> at 6 months after end of therapy. The definite cure rate for IMPAVIDO was statistically significantly higher than the cure rate for placebo.  </p>
<table>
<caption><span>Table 7: Efficacy of IMPAVIDO Compared to Placebo in the Treatment of <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">Cutaneous Leishmaniasis</span> in Colombia and Guatemala</span></caption>
<col width="42%">
<col width="37%">
<col width="37%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>The difference (95% CI) between groups is 36.8% (20.1%, 53.4%) with P-value&lt;0.0001.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td valign="top"></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">IMPAVIDO</span></p></td>
<td align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td valign="middle"><p class="First">Definite Cure<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td align="center" valign="middle"><p class="First">59/89 (66%)</p></td>
<td align="center" valign="middle"><p class="First">13/44 (30%)</p></td>
</tr>
<tr>
<td valign="middle"><p class="First">Â Â Colombia</p></td>
<td align="center" valign="middle"><p class="First">40/49 (82%)</p></td>
<td align="center" valign="middle"><p class="First">9/24 (38%)</p></td>
</tr>
<tr class="Last">
<td valign="middle"><p class="First">Â Â Guatemala</p></td>
<td align="center" valign="middle"><p class="First">19/40 (48%)</p></td>
<td align="center" valign="middle"><p class="First">4/20 (20%)</p></td>
</tr>
</tbody>
</table>
<p>An additional study of IMPAVIDO was conducted in Bahia and Manaus, two regions in Brazil  where respectively <span class="Italics">L. braziliensis</span> and <span class="Italics">L. guyanensis</span> are epidemiologically the prevalent infecting pathogens.  Adolescent/adult patients aged 12-65 years received IMPAVIDO orally for 28 days. IMPAVIDO target dose was 2.5 mg/kg/day: patients weighing 15-29 kg received 50 mg once daily, patients weighing 30-45 kg received 50 twice mg daily and patients weighing &gt; 46 kg received 50 mg three times daily.  The efficacy criteria were initial cure (complete re-epithelialization of the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> at 2 months after the end of therapy) followed by definite cure (complete re-epithelialization at 6 months after the end of therapy).  Definite cure rate in patients aged â‰¥12 years was 27/40 (67.5%) for Manaus, Brazil and 34/40 (85%) for Bahia, Brazil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3030a523-88b2-42e1-849e-bb90ca5fb552"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Treatment of Mucosal Leishmaniasis</h2>
<p class="First">A single arm study was conducted to evaluate the efficacy of IMPAVIDO capsules for the treatment of mucosal leishmaniasis. The study was conducted in Bolivia where <span class="Italics">L. braziliensis</span> is epidemiologically the prevalent species.</p>
<p>Seventy nine (79) patients â‰¥18 years of age with a <span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">cutaneous leishmaniasis</span> <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> plus parasites observed or cultured from lesion material or a positive skin test, and no clinically significant concomitant disease received miltefosine at a target dose of 2.5 mg/kg/day for 28 days.  By 12 months after the end of therapy, 49 of the patients (62%) had complete resolution of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, infiltration and erosion from the involved mucosal sites.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_1dfbaf8a-b5ae-4b35-a39e-6d4dd3f7d9dc"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each IMPAVIDO capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. IMPAVIDO capsules are supplied in a folded peel/push-through <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card.  Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card contains 14 capsules. Each carton contains two <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards (NDC 61744-050-01).</p>
<p>Store at 20-25 Â°C (68-77 Â°F); excursions permitted to 15-30 Â°C (59-86 Â°F). [See USP Controlled Room Temperature].  Protect from moisture. </p>
<p>Dispense only in the original carton.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_bf5a7d66-9fe4-4e88-8041-de7f42a380ad"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Bold">See the FDA-approved Medication Guide</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bad36f33-4770-42f7-b19b-71d1ce0ffd04"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Dosing Instructions</h2>
<dl>
<dt>â€¢</dt>
<dd>IMPAVIDO is administered with food to ameliorate gastrointestinal side effects.</dd>
<dt>â€¢</dt>
<dd>Instruct the patient to swallow the capsule whole and not to chew it or break it apart.  Instruct the patient to complete the full course of therapy. </dd>
<dt>â€¢</dt>
<dd>Inform the patient that <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> are common side effects of therapy with IMPAVIDO and instruct the patient to inform their healthcare provider if these gastrointestinal side effects are severe or persistent. Instruct the patient to consume sufficient fluids to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and, consequently, the risk of kidney injury.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3c68a3ab-8ab3-4ac7-b77e-b380ff77b068"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Females and Males of Reproductive Potential</h2>
<dl>
<dt>â€¢</dt>
<dd>Advise women of reproductive potential to use effective contraception during IMPAVIDO therapy and for 5 months after therapy ends <span class="Italics">[see <a href="#ID_c76ef055-d392-485b-a069-20aa588290d0">Boxed Warning</a> and Use in Specific Populations (<a href="#ID_99d19d9b-cb99-4124-aa6f-aea2f0228a62">8.1</a>, <a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>Advise women who use oral contraceptives to use additional non-hormonal or alternative method(s) of effective contraception during IMPAVIDO therapy if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and/or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs <span class="Italics">[see Warnings and Precautions (<a href="#ID_9bdb2096-66ea-4b99-bfb3-f34c47dc13ec">5.7</a>) and Use in Specific Populations (<a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>Advise nursing mothers not to breastfeed during IMPAVIDO therapy and for 5 months after therapy is completed <span class="Italics">[see Use in Specific Populations (<a href="#ID_247ef062-15b5-4aeb-bf91-d6f612ba9497">8.3</a>)]</span>.</dd>
<dt>â€¢</dt>
<dd>Advise women and men that IMPAVIDO caused <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> in male rats, impaired fertility in female rats, and caused atresia in ovarian follicles in female dogs. Advise patients that the potential of impaired fertility in humans has not been adequately evaluated <span class="Italics">[see Warnings and Precautions (<a href="#ID_49b34fcc-6afc-41cd-b77e-2c4405babc2c">5.2</a>) and Use in Specific Populations (<a href="#ID_a7f46d85-c404-4fcf-bf9e-4c777ab19c15">8.8</a>)]</span>.</dd>
</dl>
<p class="First">Distributed by:<br>Paladin Therapeutics Inc.<br>Corporation Trust Center<br>1209 Orange Street<br>Wilmington, DE 19801<br>USA</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_486450fa-515b-4273-b3a4-0522c1f569e2"></a><a name="section-16"></a><p></p>
<h1>Medication Guide</h1>
<p class="First">IMPAVIDOÂ® (Im-PA-vee-do)<br>(miltefosine)<br>Capsules</p>
<p>Read this Medication Guide before you receive IMPAVIDO. This information does not take the place of talking to your healthcare provider about you medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about IMPAVIDO?</span></p>
<p><span class="Bold">IMPAVIDO may cause serious risks to pregnancy:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Do not take IMPAVIDO if you are pregnant. If you take IMPAVIDO during pregnancy, your baby is at risk for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.  </dd>
<dt>â€¢</dt>
<dd>Women who can become pregnant should use effective birth control (contraception) during IMPAVIDO treatment and for 5 months after stopping IMPAVIDO treatment. Discuss with your healthcare provider which birth control method is right for you.</dd>
<dt>â€¢</dt>
<dd>If you become pregnant while taking IMPAVIDO, tell your healthcare provider right away. Talk to your healthcare provider about taking part in the IMPAVIDO Pregnancy Registry. This is a study to learn how IMPAVIDO affects pregnancy and babies. You can enroll in this registry by calling xxxxxxx.</dd>
</dl>
<p><span class="Bold">What is IMPAVIDO?</span></p>
<p>IMPAVIDO is prescription medicine used to treat certain types of leishmaniasis:</p>
<dl>
<dt>â€¢</dt>
<dd>visceral leishmaniasis (affecting your internal organs) </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4080607" conceptname="Cutaneous leishmaniasis">cutaneous leishmaniasis</span> (affecting the skin) </dd>
<dt>â€¢</dt>
<dd>mucosal leishmaniasis (affecting the nose, mouth and throat) </dd>
</dl>
<p>It is not known if IMPAVIDO is safe and effective in children under 12 years of age.</p>
<p><span class="Bold">Who should not take IMPAVIDO? Do not take IMPAVIDO if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are pregnant</dd>
<dt>â€¢</dt>
<dd>have SjÃ¶gren-Larsson-Syndrome</dd>
<dt>â€¢</dt>
<dd>are allergic to miltefosine or any of the ingredients in IMPAVIDO. See the end of this leaflet for a list of the ingredients in IMPAVIDO.</dd>
<dt>â€¢</dt>
<dd>are a woman who can become pregnant and have not had a pregnancy test. Women who can get pregnant must have a urine or blood pregnancy test before taking IMPAVIDO.</dd>
<dt>â€¢</dt>
<dd>are a woman who can become pregnant and you are not willing to use effective birth control during IMPAVIDO treatment and for 5 months after treatment</dd>
</dl>
<p><span class="Bold">Before you take IMPAVIDO, tell your healthcare provider about all of your medical conditions, including if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have kidney or liver problems. Your healthcare provider should do blood tests to check your kidneys and liver before you start, during and after your treatment with IMPAVIDO.</dd>
<dt>â€¢</dt>
<dd>are pregnant or planning to become pregnant. IMPAVIDO may harm your unborn baby.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed.  It is not known if IMPAVIDO passes into your breast milk.  Talk to your healthcare provider about the best way to feed your baby if you take IMPAVIDO. You should avoid breastfeeding while you take IMPAVIDO and for 5 months after you stop taking IMPAVIDO.</dd>
</dl>
<p>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p><span class="Bold">How should I take IMPAVIDO?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take IMPAVIDO exactly as your healthcare provider tells you to.  </dd>
<dt>â€¢</dt>
<dd>Complete your full 28 day IMPAVIDO treatment.</dd>
<dt>â€¢</dt>
<dd>Take IMPAVIDO capsules whole. Do not break, crush, dissolve, or chew IMPAVIDO before swallowing. </dd>
<dt>â€¢</dt>
<dd>Take IMPAVIDO with food to help reduce stomach problems.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of IMPAVIDO?</span></p>
<p><span class="Bold">IMPAVIDO may cause serious side effects, including: </span></p>
<p><span class="Bold">See â€œWhat is the most important information I should know about IMPAVIDO?â€?</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Fertility problems in male and female rats and abnormal menstrual cycle in female dogs. </span>It is not known if IMPAVIDO causes fertility problems in men or women </dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4270932" conceptname="Pain in testicle">Testicular pain</span> and absent or decreased ejaculation </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Kidney and liver problems</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Stomach problems</span>. IMPAVIDO can cause <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Call your healthcare provider right away if you have severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not go away. Drink a lot of water to help prevent <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> while you are having <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Decreased effectiveness of oral contraceptive pills</span>. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may cause your birth control pills to be less effective at preventing pregnancy. Use an extra method of birth control, such as male condoms with spermicide, until you are no longer having <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Decrease in platelets </span>(which are blood cells that help blood clot).</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Serious Skin Problems. </span>IMPAVIDO can cause a serious skin problem called <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>. If you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> while taking IMPAVIDO, stop taking IMPAVIDO right away and call your healthcare provider.</dd>
</dl>
<p><span class="Bold">The most common side effects of IMPAVIDO include: </span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Other side effects include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, skin <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and abnormalities in liver or kidney tests.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of IMPAVIDO. For more information, ask your healthcare provider.</p>
<p>You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store IMPAVIDO?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store IMPAVIDO at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</dd>
<dt>â€¢</dt>
<dd>Protect IMPAVIDO from moisture.</dd>
</dl>
<p>Keep IMPAVIDO and all medicines out of the reach of children.</p>
<p><span class="Bold">General information about the safe and effective use of IMPAVIDO.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in this Medication Guide. Do not use IMPAVIDO for a condition for which it was not prescribed. This Medication Guide summarizes the most important information about IMPAVIDO. If you would like more information, talk to your healthcare provider or pharmacist. You can ask your healthcare or pharmacist for information about IMPAVIDO that is written for health professionals.  Do not give IMPAVIDO to other people, even if they have the same symptoms that you have.  For more information, go to www.TRADENAME.com or www.dailymed.nlm.nih.gov, or call 1-XXX-XXX-XXXX.</p>
<p><span class="Bold">What are the ingredients in IMPAVIDO?</span></p>
<p><span class="Bold">Active ingredient:</span> miltefosine</p>
<p><span class="Bold">Inactive ingredients:</span>  colloidal silicon dioxide, microcrystalline cellulose, lactose monohydrate, talc, and magnesium stearate.  The capsule shell contains gelatin, titanium dioxide, ferric oxide, and purified water.</p>
<p>Distributed by:  Paladin Therapeutics, Inc.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Issued: March 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_59acd275-4b7f-4983-8cba-544a77043952"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - CARTON</h1>
<div class="Figure">
<a name="id341063888"></a><img alt="Principal Display Panel - Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5&amp;name=d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5-02.jpg">
</div>
<p class="First">NDC 61744-050-01Â Â Â Â Â Â Â Â Â Â <span class="Bold"><span class="Italics">Paladin Therapeutics</span></span></p>
<p><span class="Bold">ImpavidoÂ®</span><br>(miltefosine) capsules<br>50 mg per Capsule</p>
<p>Rx onlyÂ Â Â Â Â Â Â Â Â Â 28 capsules</p>
<p>Contains 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards, 14 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> per card, 1 capsule per <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.<br>Active ingredient: miltefosine<br>Inactive ingredients: colloidal silicon dioxide, lactose monohydrate,<br>magnesium stearate, microcrystalline cellulose, talc. The capsule<br>shell contains gelatin, titanium dioxide ferric oxide and purified water.</p>
<p>Usual dosage: see enclosed package insert for complete<br>prescribing information.</p>
<p><span class="Bold">Keep out of reach of chidren.</span></p>
<p>Store at 20-25 Â°C (68-77 Â°F); excursions permitted<br>to 15-30 Â°C (59-86 Â°F). [See USP Controlled Room Temperature].</p>
<p>Distributed by:<br>Paladin Therapeutics Inc.<br>Corporation Trust Center<br>1209 Orange Street<br>Wilmington, DE<br>USA 19801</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IMPAVIDOÂ 		
					</strong><br><span class="contentTableReg">miltefosine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61744-050</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MILTEFOSINE</strong> (MILTEFOSINE) </td>
<td class="formItem">MILTEFOSINE</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61744-050-01</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204684</td>
<td class="formItem">09/19/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Paladin Therapeutics Inc.
							(832989383)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BASF Pharma SA</td>
<td class="formItem"></td>
<td class="formItem">480143502</td>
<td class="formItem">API MANUFACTURE(61744-050)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Haupt Pharma Amareg GmbH</td>
<td class="formItem"></td>
<td class="formItem">331334909</td>
<td class="formItem">MANUFACTURE(61744-050)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bertin Pharma</td>
<td class="formItem"></td>
<td class="formItem">262319480</td>
<td class="formItem">ANALYSIS(61744-050)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carton Service, Inc.</td>
<td class="formItem"></td>
<td class="formItem">928861723</td>
<td class="formItem">PACK(61744-050)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5</div>
<div>Set id: d6658aeb-7bc1-4eef-ad0d-0a873ddbecf5</div>
<div>Version: 1</div>
<div>Effective Time: 20140328</div>
</div>
</div>Â <div class="DistributorName">Paladin Therapeutics Inc.</div></p>
</body></html>
